clonazepam has been researched along with Sarcoma in 2 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 7.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma." | 5.08 | [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. ( Baranzelli, MC; Deligny, N; Demaille, MC; Gourmel, B; N'Guyen, M; Pichon, F, 1997) |
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 3.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cacchione, A | 1 |
| LeMaitre, A | 1 |
| Couanet, DV | 1 |
| Benhamou, E | 1 |
| Amoroso, L | 1 |
| Simonnard, N | 1 |
| Hartmann, O | 1 |
| Baranzelli, MC | 1 |
| Pichon, F | 1 |
| Gourmel, B | 1 |
| N'Guyen, M | 1 |
| Deligny, N | 1 |
| Demaille, MC | 1 |
1 trial available for clonazepam and Sarcoma
| Article | Year |
|---|---|
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Clonazepam; Dose-Response Relations | 1997 |
1 other study available for clonazepam and Sarcoma
| Article | Year |
|---|---|
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; | 2008 |